Biogen Reports Q4 2024 Earnings with Revenue Growth and Mixed Performance Across Product Lines
Biogen (BIIB) reported Q4 2024 revenue of $2.5 billion, a 3% increase from the previous quarter, though full-year revenue declined 2% compared to 2023. The company saw growth in its rare disease franchise and SKYCLARYS product, but faced challenges in its multiple sclerosis (MS) product line due to increased competition.
Tickers: $BIIB
Topics: Earnings Financial Performance Revenue Stock Performance